Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.41 |
| ▸ | DRD2 | P14416 | 5/20 | 0.40 |
| ▸ | PRCP | P42785 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3242333 | 1.00 | HTR1A (0.41) | HTR1ADRD2PRCPSIGMAR1 | |
| SCHEMBL3248230 | 1.00 | HTR1A (0.41) | HTR1ADRD2PRCPSIGMAR1 | |
| SCHEMBL3236804 | 1.00 | HTR1A (0.41) | HTR1ADRD2PRCPSIGMAR1 | |
| SCHEMBL3242790 | 0.82 | HRH3 (0.38) | HTR1ASIGMAR1 | |
| SCHEMBL3239192 | 0.82 | NOTUM (0.36) | — | |
| SCHEMBL3246223 | 0.81 | MEN1 (0.39) | — | |
| SCHEMBL3243594 | 0.78 | NOTUM (0.40) | DRD2 | |
| SCHEMBL3243592 | 0.78 | NOTUM (0.40) | DRD2 | |
| SCHEMBL3236813 | 0.78 | NOTUM (0.40) | DRD2 | |
| SCHEMBL3244851 | 0.68 | HTR1A (0.40) | HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102204-B1 | NEW AMINOPYRROLO[1,2- A]INDOLE ET AMINOPYRIDAZINO[1,6-A]INDOLE DERIVATIVES, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SERVIER LAB (FR) | 2010-05-05 | — | — | EP | claimed |
| EP-2102204-B1 | NEW AMINOPYRROLO[1,2- A]INDOLE ET AMINOPYRIDAZINO[1,6-A]INDOLE DERIVATIVES, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SERVIER LAB (FR) | 2010-05-05 | — | — | EP | disclosed |
| US-20090298813-A1 | USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES | LES LABORATOIRES SERVIER (FR) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298813-A1 | USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES | NLN, GAP43, SNCA | HTR1A 892/4885DRD2 1334/4885PRCP 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.